Safety Report of Ferumoxytol for Magnetic Resonance Imaging in Children and Young Adults. Issue 4 (April 2016)

• Record Type: Journal Article
• Authors: Muehe, Anne M.; Feng, Dan; von Eyben, Rie; Luna-Fineman, Sandra; Link, Michael P.; Muthig, Travis; Huddleston, Amy E.; Neuwelt, Edward A.; Daldrup-Link, Heike E.
• Is Part Of: Investigative radiology. Volume 51:Issue 4(2016:Apr.)
• Publication Date: 2016-04
• Subjects: ferumoxytol -- contrast media -- ferric compounds -- pediatric -- safety -- adverse events/adverse effects -- toxicity; Diagnosis, Radioscopic -- Periodicals; Radiology, Medical -- Periodicals; 616.0757
• DOI: 10.1097/RLI.0000000000000230
• Languages: English
• ISSNs: 0020-9996

Abstract

Abstract : Objective: The aim of this study was to assess the safety profile of ferumoxytol as an intravenous magnetic resonance imaging contrast agent in children. Materials and Methods: We prospectively evaluated the safety of ferumoxytol administrations as an "off-label" contrast agent for magnetic resonance imaging in nonrandomized phase 4 clinical trials at 2 centers. From September 2009 to February 2015, 49 pediatric patients (21 female and 28 male, 5–18 years) and 19 young adults (8 female and 11 male, 18–25 years) were reported under an investigator-initiated investigational new drug investigation with institutional review board approval, in health insurance portability and accountability act compliance, and after written informed consent of the child's legal representative or the competent adult patient was obtained. Patients received either a single dose (5 mg Fe/kg) or up to 4 doses of ferumoxytol (0.7–4 mg Fe/kg) intravenously, which were approximately equivalent to one third of the dose for anemia treatment. We monitored vital signs and adverse events directly for up to 1 hour after injection. In addition, we examined weekly vitals, hematologic, renal, and liver serum panels for 1 month after injection in over 20 pediatric patients. At fixed time points before and after ferumoxytol injection, data were evaluated for significant differences by a repeated measures linear mixed model. Results: Four mild adverse events, thought to be related to ferumoxytol, were observed within 1 hour of 85 ferumoxytol injections: 2 episodes of mild hypotension and 1 case of nausea in 65 injections in pediatric patients without related clinical symptoms. One young adult patient developed warmness and erythema at the injection site. All adverse events were self-resolving. No spontaneous serious adverse events were reported. At a dose of 5 mg Fe/kg or lower, intravenous ferumoxytol injection had no clinical relevance or statistically significant effect ( P > 0.05) on vital signs, hematological parameters, kidney function, or liver enzymes within 1 month of the injection. Conclusions: Ferumoxytol was overall well tolerated among 49 pediatric and 19 young adult patients experiencing various tumors or kidney transplants without major adverse events or signs of hematologic and kidney impairment or liver toxicity. Larger studies are needed to determine the incidence of anaphylactic reactions.